Mavacamten is a first-in-class, oral, selective allosteric inhibitor of cardiac myosin.It modulates cardiac contractility by decreasing actin-myosin cross-bridge formation,reducing hypercontractility and left ventricular outflow tract obstruction.
Approved Indications
Symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adultsto improve functional capacity and symptoms
Key Features
First-in-class cardiac myosin inhibitor
Targets the underlying pathophysiology of HCM
Oral, once-daily dosing
Improves exercise capacity and NYHA class
Well-established safety profile
Applications
API, intermediates, reference standards for R&D, generic registration and commercial manufacturing.
ECROBOT CO., Ltd, Business Registration Number : 220-88-71747, CEO J.W.Park, TEL : +82-2-552-7676, E-mail : E-mail : Contact us Address : (Hwanghwa B/D 11F, Yeoksam-dong)320, Gangnam-daero, Gangnam-gu, Seoul, South Korea
China [CN] 
Click enlarge Image